ORGN 186

Development of practical syntheses of VEGFR inhibitors

Robert D. Larsen, rlarsen@amgen.com¹, Yuelie Lu, yueliel@amgen.com¹, Tingjian Xiang, txiang@amgen.com¹, Ben Zhi, bzhi@amgen.com¹, Jean Baum², Pingli Liu¹, Liang Huang¹, Ying Chen, Ying@Amgen.com², Xin Wang, xinw@amgen.com¹, Richard Crockett², Doug Overland², Craig Schulz², Shawn Eisenberg², and Michael Martinelli². (1) Chemical Process Research and Development, Amgen Inc, One Amgen Center Drive, Mailstop: 29-M-A, Thousand Oaks, CA 91320, (2) Chemistry Process Research and Development, Amgen Inc, One Amgen Center Drive, Mailstop: 29-M-A, Thousand Oaks, CA 91320

Vascularization or angiogenesis is key to the growth of tumors. One mechanism for halting angiogenesis is through the pro-angiogenic factor VEGFR (vascular endothelial growth factor receptor) or KDR (kinase domain receptor). A new class of VEGF inhibitors has been discovered at Amgen. Process development of this structural series will be presented.

The Role of Organic Synthesis in Early Clinical Drug Development
8:30 AM-12:00 PM, Monday, 27 March 2006 Georgia World Congress Center -- C303/304/305, Oral

Division of Organic Chemistry

The 231st ACS National Meeting, Atlanta, GA, March 26-30, 2006